- Home
- SKYE vs NRO Comparison
SKYE vs NRO Comparison
Compare SKYE & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- NRO
- Stock Information
- Founded
- SKYE 2012
- NRO 2003
- Country
- SKYE United States
- NRO United States
- Employees
- SKYE N/A
- NRO N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- SKYE Health Care
- NRO Finance
- Exchange
- SKYE Nasdaq
- NRO Nasdaq
- Market Cap
- SKYE 115.9M
- NRO 156.7M
- IPO Year
- SKYE N/A
- NRO N/A
- Fundamental
- Price
- SKYE $3.98
- NRO $3.24
- Analyst Decision
- SKYE Buy
- NRO
- Analyst Count
- SKYE 6
- NRO 0
- Target Price
- SKYE $16.60
- NRO N/A
- AVG Volume (30 Days)
- SKYE 2.2M
- NRO 239.4K
- Earning Date
- SKYE 08-08-2025
- NRO 01-01-0001
- Dividend Yield
- SKYE N/A
- NRO 11.41%
- EPS Growth
- SKYE N/A
- NRO N/A
- EPS
- SKYE N/A
- NRO N/A
- Revenue
- SKYE N/A
- NRO N/A
- Revenue This Year
- SKYE N/A
- NRO N/A
- Revenue Next Year
- SKYE N/A
- NRO N/A
- P/E Ratio
- SKYE N/A
- NRO N/A
- Revenue Growth
- SKYE N/A
- NRO N/A
- 52 Week Low
- SKYE $1.14
- NRO $2.51
- 52 Week High
- SKYE $7.47
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- SKYE 60.88
- NRO 52.08
- Support Level
- SKYE $3.65
- NRO $3.19
- Resistance Level
- SKYE $4.75
- NRO $3.27
- Average True Range (ATR)
- SKYE 0.71
- NRO 0.04
- MACD
- SKYE 0.00
- NRO 0.00
- Stochastic Oscillator
- SKYE 48.55
- NRO 65.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").